Neuroactive Steroid Compounds for GABAA-Mediated Brain Excitability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that can modulate brain excitability and treat CNS-related disorders, as existing agents like benzodiazepines have limitations and new neuroactive steroids are required to improve therapeutic options.
Innovation Solution
Development of compounds, such as those represented by Formula (I), which act as GABA modulators, specifically targeting the GABAA receptor to regulate brain excitability and treat CNS-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing agents like benzodiazepines are used to modulate brain excitability, then therapeutic effects are achieved, but limitations in treatment options and efficacy remain
Solution Approach 1:
The patent applies parameter changes by developing novel neuroactive steroid compounds with modified molecular structures (Formula I) that interact with the GABA-A receptor at the neuroactive steroid binding site. These structural parameter changes create new therapeutic agents with improved efficacy and expanded treatment options for CNS disorders compared to existing benzodiazepines
Solution Approach 2:
The invention employs composite materials by designing compounds that combine specific structural elements (steroid backbone with various substituent groups at positions R1-R21) to create multifunctional neuroactive agents. These composite molecular structures enable simultaneous optimization of receptor binding affinity, pharmacokinetic properties, and therapeutic efficacy
2Adaptability or versatility
If new neuroactive steroid compounds are developed to expand treatment options, then therapeutic versatility improves, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecular structure into distinct functional segments: the steroid core structure and various substituent groups (R1-R21) at specific positions. This modular approach allows systematic optimization of each segment's properties while maintaining overall compound functionality and simplifying structure-activity relationship analysis
Solution Approach 2:
The invention implements universality by designing a platform compound (Formula I) with multiple可变 substituents that can be systematically modified to target different CNS disorders. This universal molecular framework serves multiple therapeutic purposes while maintaining a consistent core structure, reducing the need for entirely new compound designs for different indications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively modulate brain excitability and provide therapeutic benefits for conditions like depression, anxiety, and seizure activity by interacting with the GABAA receptor, offering improved treatment options for CNS-related disorders.
Implementation Method 1
GABA interacts with its recognition site on the GRC to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell. An intracellular increase in the levels of this anion causes hyperpolarization of the transmembrane potential, rendering the neuron less susceptible to excitatory inputs
Data Source
AI summary
Provided herein is a compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R16b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.